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VILLANOVA ENVIRONMENTAL
LAW JOURNAL
VOLUME XX 2009 NUMBER 1
COLLISION COURSE? SCIENCE, LAW, AND REGULATION IN
THE EMERGING SCIENCE OF LOW DOSE TOXICITY
JODY A. ROBERTS*
I. INTRODUCTION
Bisphenol-A (BPA) and phthalates are no longer words strictly
contained in a chemist's lexicon. In recent months, United States
citizens have begun to use these words in correlation with the in-
creased press coverage of these two synthetic chemicals. The atten-
tion surrounding BPA peaked earlier this year when Nalgene, a
maker of polycarbonate water bottles, especially popular with out-
door outfitters, announced the removal of its line of bottles made
with BPA with a plan to replace them with a BPA-free formulation.'
The news was particularly striking because portable, reusable water
bottles have increasingly become the more "eco-friendly" choice in
response to the recent revolt against bottled water and bottled
water manufacturers. 2 Nalgene's announcement was not the only
shake-up in the BPA market that week; it was the crescendo to a
* Jody Roberts is Program Manager for Environmental History and Policy in
the Center for Contemporary History and Policy at the Chemical Heritage Founda-
tion in Philadelphia. Roberts' work explores the intersection of emerging chemical
sciences and technologies and issues of health and environment. This paper builds
on a longer conversation extending from a conference organized in March 2007
that brought together researchers working in the fields of endocrine disrupting
chemicals and human biomonitoring and extends through the 2007 Villanova En-
vironmental Law Journal Symposium on low dose toxicity. The report from the
CHF conference, "New Chemical Bodies: A Conversation on Human Biomonitor-
ing and Endocrine-Disrupting Chemicals" has just been published.
1. See Ian Austen, Bottle Maker to Stop Using Plastic Linked to Health Concerns,
N.Y. TiMES, Apr. 18, 2008, at Cl (explaining Nalgene's decision to stop using BPA).
2. See Lisa Stiffier, Drink Tap Water, Not Bottled, City Urges, SEATILE POST-INTEL-
LIGENCER, May 7, 2008, available at http://seattlepi.nwsource.com/local/362153_
seattlewater08.html (explaining how bottled water harms environment); See also
Thomas Kostigen, U.S. Mayors Ban Taxpayer Funds for Bottled Water, DiscoVER, June
25, 2008 (noting majority at U.S. Conference of Mayors meeting in Miami voted to
stop spending money on bottled water due to wasteful effects).
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week filled with buzzing noise from Canadian and U.S. regulatory
agencies concerning the chemical. 3 Although none of the parties
involved wanted to admit that BPA might cause problems, pressure
from Non-Governmental Organizations (NGOs), the market and a
committed group of international scientists have made change hap-
pen regardless of governmental assistance.4
Phthalates have for the most part escaped the high-profile pub-
lic scrutiny characterizing the recent attention on BPA. That is not
to say, however, that phthalates have received a free pass. Indeed,
while the BPA debate has lingered, phthalates have already been
marked for replacement in children's toys in the European Union
(EU), an effect that is rippling across the oceans.5 These issues also
followed on the heels of other high-profile events in recent
months.6 For example, toys coming to the U.S. from China were
found to contain intolerably high levels of lead.7 Overall, the past
eighteen months have been tense for toys, chemicals and interna-
tional trade.
3. Compare News Release, Health Canada, Government of Canada Takes Ac-
tion on Another Chemical of Concern: Bisphenol A, (April 18, 2008), available at
http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/-2008/2008-59-eng.php#cont (ex-
plaining that Canadian government was taking action against Bisphenol A to pro-
tect citizens' health), and Sarah Schmidt, Ottawa to Declare Bisphenol A Toxic,
NATIONAL POST (Canada), April 17, 2008, available at http://www.nationalpost.
com/news/story.html?id=452933 (explaining why Canadian government declared
Bisphenol A toxic), with NAT'L TOXICOLOGY PROGRAM, UNITED STATES DEP'T OF
HEALTH & HUMAN SERXS., DRAFT NTP BRIEF ON BISPHENOL A (2008), http://
cerhr.niehs.nih.gov/chemicals/bisphenol/BPADraftBriefVF 04 14_08.pdf (dis-
cussing Bisphenol A effects caused by exposure to it); and Rhitu Chatterjee, NTP
Brief on BPA Receives Mixed Peer Review ENVTL. SCI. & TECH. 6312, 6312 (2008) (de-
tailing mixed reviews that NTP's board of scientific advisers gave draft brief).
4. See Mark Gunther, WalMart: The New FDA, FORTUNE, July 16, 2008, available
at http://money.cnn.com/2008/07/15/magazines/fortune/gunther bpa.for-
tune/index.htm (illustrating how products containing BPA were being forced out
not by regulators, but by advocacy groups, including major retailers, such as
WalMart).
5. See Council Directive 2005/84/EC, art. 3, 2005 O.J. (L 344) 40, 42 (EC)
(prohibiting use of certain phthalates in children's toys); see also MARK SCHAPIRO,
EXPOSED: THE ToxIc CHEMISTRY OF EVERYDAY PRODUCTS AND WHAT'S AT STAKE FOR
AMERICAN POWER 42-66 (2007) (explaining consequences of Directive on United
States).
6. See Louise Story, Lead Paint Prompts Mattel to Recall 967, 000 Toys, N.Y. TIMES,
Aug. 2, 2007, at C1 (explaining that Mattel has recalled toys made in China, such
as Barbie dolls and Hot Wheels cars, because toys were covered in lead paint); see
also A Tough Year for "Made in China", Marketplace (Marketplace Internet broadcast
Dec. 28, 2007) (audio available at http://marketplace.publicradio.org/display/
web/2007/12/28/brand chinaq/#) (reporting stories of lead paint in Chinese-
made toys). Cf Eric Lipton, Some Baby Bibs Said to Contain Levels of Lead, N.Y. TIMES,
Aug. 15, 2007, at C1 (reporting Chinese-made baby bibs containing lead sold at
Toys "R" Us stores may be harmful to children).
7. See id. (discussing levels of toxicity in toys arriving from China).
[Vol. XX: p. I
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Despite this recent attention, larger questions still loom, such
as how did this situation come about in the first place? Lawmakers
are currently revisiting the decades old Toxic Substances Control
Act (TSCA) regulations with hopes of understanding how to
breathe new life into this seemingly exhausted and ineffective law.8
Responses from individual consumers and consumer advocacy
groups certainly helped pave the way for the recent hearings on
Capitol Hill concerning the use of BPA and phthalates in consumer
goods as well as the introduction of the Kid-Safe Chemical Act.9
The Act would initiate an overhaul of the system by bringing atten-
tion to the exposures of children and other vulnerable groups,
which would require new pre-market testing protocols and the insti-
tution of ongoing biomonitoring studies for public health
tracking.10
Building on this recent momentum, this Article addresses is-
sues concerning how to make law and regulation more accommo-
dating to emerging science. This Article is intended to be part of a
larger conversation that has also found a significant place in the
pages of this Journal.1  This Article, more specifically, is a com-
ment in response to an article published in the previous issue of
this Journal by Carl F. Cranor.12 Finally, this Article will lay out the
very brief history that links Cranor's paper "Do You Want to Bet
Your Children's Health on Post-Market Harm Principles?", this pa-
per, and their similar roots.
Cranor's article emerged from his talk at the Villanova Univer-
sity School of Law in the Fall of 2007. That Symposium grew out of
a conference organized earlier that year at the Chemical Heritage
Foundation in Philadelphia, Pennsylvania, which explored the in-
8. See generally Democrats Roll Out Broad Chemical Risk Management Bill, RisK POL.
RFP. (Inside EPA/Def. Envt. Alert), June 10, 2008) (discussing need for change in
TSCA to account for changes in technology).
9. H.R. 6100, 110th Cong. (2008), available at http://www.govtrack.us/con-
gress/bill.xpd?bill=h 110-6100.
10. Compare Kid-Safe Chemicals Act of 2008, H.R. 6100, 110th Cong. (2d Sess.
2008) (detailing bill before House of Representatives for Kid-Safe Chemicals Act of
2008), with Kid-Safe Chemicals Act of 2008, S. 3040, 110th Cong. (2d Sess. 2008)
(detailing bill before Senate for Kid-Safe Chemicals Act of 2008).
11. See generally Carl F. Cranor, Do You Want to Bet Your Children's Health on Post-
Market Harm Principles?, 19 VILL. ENVTL. LJ. 251 (2008); David B. Fischer, Na-
notechnology - Scientific and Regulatory Challenges, 19 VILL. ENVTL. L.J. 315 (2008);
A.W. Harris, Derogating the Precautionary Principle, 19 VILL. ENrrL. L.J. 1 (2008);
Keith J. Jones, Endocrine Disruptors and Risk Assessment: Potential For a Big Mistake, 17
VILL. ENIVL. L.J. 357 (2006) (observing extensive treatment and high importance
of low-dose toxicity within pages of Villanova Environmental Law Journal).
12. See Cranor, supra note 11, at 253-55 (noting previous discussion on low-
dose toxicity).
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tersecting issues of human biomonitoring studies and research into
endocrine-disrupting chemicals.' 3 The conference brought to-
gether practitioners of the various sciences involved in these issues,
as well as historians, sociologists, public health professionals and
legal scholars. The Symposium at the Villanova University School
of Law refocused the discussion from the earlier conference by ex-
amining more intently the potential legal ramifications of low-dose
toxicity issues. The Symposium organizers deserve much credit be-
cause these issues were not squarely on the radar when the Sympo-
sium was being planned. Their decision to go ahead with this topic
demonstrated a great deal of foresight and courage; and the most
tangible result is that we now have a legal forum, by way of this
Journal, to have this discussion.
Cranor took the issue head-on by arguing that the current
modes of regulating chemicals in the U.S. are woefully inadequate
for protecting the health of the citizenry in his provocatively titled
article "Do You Want to Bet Your Children's Health on Post-Market
Harm Principles?"'14 Cranor points to the tremendous gap that ex-
ists among methods and assumptions in U.S. testing protocol and
the current state of the toxicological sciences.1 5 He also outlines
the inadequacies of a system that waits for harm to occur before
action is taken.16 Cranor suggests two alternative approaches as po-
tential remedies: one drawing on the Registration, Evaluation, Au-
thorization, and Restriction of Chemical Substances (REACH)
model currently being instituted in the EU, and, alternatively, an
approach that rethinks the relationship between individuals and
the chemicals that comprise our world. 17 Additionally, he lays the
groundwork for a form of trespass law that would not only make
harm from chemical exposures a legal injury, but would also make
13. SeeJODY A. ROBERTS, CTR. FOR CONTEMPORARY HISTORY & POLICY, CHEM.
HERITAGE FOUND., NEW CHEMICAL BODIES: A CONVERSATION ON HUMAN Bi-
OMONITORING AND ENDOCRINE-DISRUPTING CHEMICALS 1 (2008), available at http://
www.chemheritage.org/pubs/New-Chemical-Bodies.pdf. (referencing conference
organized by Chemical Heritage Foundation which in part led to Villanova Law
School Symposium).
14. See Cranor, supra note 11, at 251 (mentioning observations on low-dose
toxicity).
15. See id. at 252 (observing U.S. allowance of products to enter commerce
without testing).
16. See id. (describing how U.S. testing protocol allows citizens to be harmed
prior to action to remove harmful product).
17. See id. at 252-53 (outlining Cranor's two alternative models for handling
low-dose toxicity issues).
Vol. X : p. I
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the mere presence of an unwanted chemical a moral violation of an
individual. 18
While Cranor's article focuses on the problems relating to
emerging science, David B. Fischer's article, published in the same
issue of the Journal, addresses a subset of this broader problem.
Fischer's article, "Nanotechnology - Scientific and Regulatory Chal-
lenges," looks at the introduction of a new class of materials and the
pressures placed on the regulatory system. 19 Fischer's choice of ti-
tle is interesting. Instead of highlighting only scientific challenges
to regulation or regulatory challenges to science, the title empha-
sizes how these new materials challenge both communities.
This is the crux of the problem and the idea behind the title of
this Article. The challenges that emerging technosciences pose for
their respective scientific and regulatory communities are inti-
mately linked, but they are not the same. Do new nanomaterials,
for example, place science, law and regulation on a collision
course?
The following will provide a closer look at some of the issues of
low-dose toxicity, its history, and the challenges that it poses in the
context of a greater concern for emerging science; this case is
clearly only one of many that have pushed the limits of the relation-
ship between science and regulation in recent years. I am tempted
here to use the term "regulatory science" to describe the place
where the tension exists. Yet, while this phrase is not uncommon, it
already implies a conclusion to the debate about whether or not
science done for science and science done for regulation are differ-
ent in kind.
Following this introduction, a more thorough exploration of
the articles by Cranor and Fischer is offered. The thought experi-
ment in which Cranor engages, and the conclusions he provides,
will be emphasized. The discussion about Fischer's article will focus
more on nanomaterials as a special subset of the more general
problem that Cranor highlighted. Of particular interest here, how-
ever, is the question of whether nanomaterials, which present many
of the same possible troubles that are dealt with under the low-dose
category, can be accommodated within either of the systems that
Cranor suggests, or whether they require all new regulations be-
18. See id. at 252 (noting trespass model).
19. See Fischer, supra note 11, at 315 (explaining new field of nanotechnology
and resulting affects on regulatory system).
2009]
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cause of their novel properties. 20 The conclusion is a call to open
up the conversation on the ways in which emerging science and its
technoscientific products might be accommodated within the regu-
latory system. Whether this requires a retooling of existing regula-
tions, as Fischer might suggest, or will necessitate overhauling
philosophical foundations in such a way that entirely new methods
will be necessary, remains uncertain and debatable. 21 This Article is
intended to add some momentum to that debate.
II. Low-DosE Toxicrry AND THE PROBLEM OF EMERGING SCIENCE
Current practices in the toxicological sciences, at least as ap-
plied to regulatory situations, operate within the paradigm best
characterized by the centuries-old saying, "the dose makes the
poison."2 2 That is to say, toxicology generally operates under the
assumption that everything is poisonous at some level; therefore,
the job of toxicologists rests in uncovering what that dose is.23 This
thinking provides the foundation for the LD50 , the lethal dose for
50% of the population tested, which results in the determination of
safe limits of exposure. 24 Maximum allowable exposures and doses,
which differ depending upon whether discussing occupational stan-
dards or environmental standards, frequently change in response to
20. See Joachim Schummer, The Impact of Nanotechnologies on Developing Coun-
tries, in NANOETHICS: THE ETHICAL AND SCIENTIFIC IMPLICATIONS OF NA-
NOTECHNOLOGY 261, 263 (Fritz Allhoff et al. eds., 2007) (discussing different
approaches to defining technology and implications of each approach).
21. See Fischer, supra note 11, at 325-31 (discussing different regulatory chal-
lenges nanomaterials present and proposals for meeting those challenges by vari-
ous groups).
22. PARACELSUS, FOUR TREATISES OF THEOPHRASTUS VON HOHENHEIM CALLED
PARACELSUS, 21-2 (Henry E. Sigerist ed., Johns Hopkins Univ. Press 1996) (1941).
The original quote comes from Theophrastus Bombastus von Hoenheim, better
known as Paracelsus, a fifteenth century iatrochemist. Id. The context, long since
forgotten in the frequent reiterations of this quote is worth noting. Paracelsus,
under attack from other apothecaries and medical practitioners for his use of sup-
posed poisons for healing purposes defended his actions by explaining that every-
thing was poisonous in some quantity. Id. at 21-4. It was therefore the duty of the
practitioner to know the difference between the doses and intentions. Id. Much
has changed in medicine since the fifteenth century, but listening to current ex-
hortations on the toxicology of synthetic chemicals might lead some to believe that
more is the same than we realize.
23. See John Doull, Toxicology Comes of Age, 41 ANN. REv. PHARMACOLOGY &
TOXICOLOGY 1, 16 (2001) (discussing principle of "the dose makes the poison").
"Based on this principle [that "the dose makes the poison"], toxicologists conclude
that there are no safe chemicals will be toxic under some conditions of exposure.
Conversely, we also conclude that there is no chemical that cannot be used safely
by simply reducing exposure." Id.
24. See id. (explaining that determining threshold for chemical's adverse ef-
fects is required to define safe and dangerous toxic levels).
[Vol. XX: p. I
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new information, new instrumentation (that allows analytical chem-
ists to see ever smaller concentrations) and public health crises.
The most obvious example, perhaps, is the changing conceptions of
harmful blood lead levels. 25 Despite its widespread use in the U.S.
for the better part of the twentieth century, lead has been a known
toxicant for centuries. 26 Over time, a combination of activism,
politics and information from public health advocates, pediatri-
cians and parents, succeeded in lowering the allowable limits, thus
producing one of the few regulatory success stories for U.S. public
health.27
Converging sciences and technologies are making the case for
a new approach to be taken in regulatory toxicology. 28 The first, as
outlined above, relates to the ways in which scientific advances in
other fields, such as endocrinology, have found their way into dis-
cussions of toxicology. 29 Adopting endocrinology data, however,
involves more than the assimilation of facts; the conceptual basis for
thinking through mechanisms of action is entirely different in en-
docrinology versus toxicology. Traditional toxicology works off of
the idea that the relationship between dose and response is linear
(which is why we can test a small range of doses and extrapolate in
each direction), whereas endocrinology views the body as a system
responding to signals from various chemicals, including hormones,
or chemicals that can mimic the function of hormones. 30 The view
25. See generally GERALD MARKOWITZ & DAVID ROSNER, DECEIT AND DENIAL: THE
DEADLY POLITICS OF INDUSTRIAL POLLUTION, 119-35 (2002) (noting change in time
of standards for harmful blood lead levels).
26. See id. (reiterating that although the dangers of lead have been known for
sometime, U.S. has continued widespread use of lead).
27. See id. (discussing efforts made and challenges faced by activists attempt-
ing to reduce all allowable exposure limits for lead).
28. See Doull supra note 23, at 17-18 (discussing flawed assumptions in early
regulatory efforts to estimate exposure limits and subsequent theories for estimat-
ing limits); see also Frederick S. vom Saal & Claude Hughes, An Extensive New Litera-
ture Concerning Low-Dose Effects of Bisphenol A Shows the Need for a New Risk Assessment,
113 ENVTL. HEALTH PERSP. 926, 931 (2005) (urging for new risk assessment on BPA
exposure levels and urging reexamination of assumption justifying linear-thresh-
old model used in risk assessments).
29. See Andrea C. Gore et al., Endocrine Disruption for Endocrinologists (and
Others), ENDOCRINOLOGY, June 2006, at S1, S1 (mentioning scientists, physicians,
clinical scientists, and epidemiologists at conference discussing endocrine disrup-
tion); see also David Crews & John A. McLachlan, Epigenetics, Evolution, Endocrine
Disruption, Health, and Disease, ENDOCRINOLOGY, June 2006, S4, S4-S9 (discussing
approach to examining whether endocrine disruptors can participate in evolution-
ary process).
30. SeeJohn A. McLachlan, Environmental Signaling: What Embryos and Evolution
Tell Us About Endocrine Disrupting Chemicals, 22 ENDOCRINE REVS. 319, 320 (2001)
(describing endocrine system). The endocrine system has been described as "an
integrated network of chemical signals." Id.
2009]
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of the body as a system in constant communication with its environ-
ment disrupts the traditional view of linear dose-response, making
extrapolation not only impossible, but potentially misleading.
Practically none of these advances would have been possible
without the tremendous advances that have taken place in analyti-
cal and instrumental technologies and experimental methods in re-
cent years. 31 These new methods and machines have aided
scientists in seeing more of these chemicals in new places, namely
within humans. 32 One result has been the increasing number of
human biomonitoring studies now available. 33 While the U.S. gov-
ernment has been engaged in these activities for several decades,
state health organizations, NGOs and other countries are exploring
ways of utilizing this data for monitoring and tracking public
health. 34 Just what information can be gleaned from these studies,
beyond the obvious fact of exposure, remains to be determined.
Unfortunately, due to limited information linking specific chemi-
cals with either chronic exposure or life-long storage of synthetic
chemicals, there is little direct health information that can be extra-
polated from these studies. 35
Despite new evidence, new science, new machines, and new in-
formation which together indicate that we have all become reposi-
tories of our modern world, little has been done to incorporate
these findings into U.S. regulatory practice. There have been sev-
eral obstacles, but two of them are most noteworthy. The U.S. Envi-
ronmental Protection Agency (EPA)'s Endocrine Disruptor
Screening and Testing Advisory Committee (EDSTAC), formed in
31. See e.g., COMMONWEAL BIOMONITORING RES. CTR., TAKING IT ALL IN: Docu-
MENTING CHEMICAL POLLUTION IN CALIFORNIANS THROUGH BIOMONITORING 6
(2005) (observing advances not possible without technology).
32. See id. (noting impact of new methods).
33. See id. (commenting on new results). See also, CTR. FOR DISEASE CONTROL
& PREVENTION, 2005 THIRD NATIONAL REPORT ON HUMAN EXPOSURE TO ENVIRON-
MENTAL CHEMICALS 1-2 (2005), available at http://www.cdc.gov/exposurereport/
pdf/thirdreport.pdf (detailing new statistics); Sonya Lunder et al., Fire Retardants
in Toddlers and Their Mothers, ENVrL. WORKING GROUP, Sept. 2008, http://
www.ewg.org/reports/pbdesintoddlers (finding that children had more chemicals
in blood than mothers); Rebecca Sutton, Teen Girls'Body Burden of Hormone-Altering
Cosmetics Chemicals, ENVTrL. WORKING GROUP, Sept. 2008, (discussing exposures to
chemicals in teen girls).
34. See generally Ken Sexton et al., Human Biomonitoring of Environmental Chemi-
caLs, 92 Am. SCIENTIST 38 (2004) (discussing history and potential in
biomonitoring).
35. See generally Richard Jackson et al., Will Biomonitoring Change how we Regu-
late Toxic Chemicals?, 30 J.L. MED. & ETHICS 177, 182 (Supp. 2002) (urging that
biomonitoring can help regulatory decision-making through assessing exposure
levels).
[Vol. XX: p. I
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1996, was charged with developing a chemical screening program
to test manufactured chemicals for possible endocrine-disrupting
activity.36 EDSTAC was given two years to complete the set-up
phase at which point the EPA would implement these new proce-
dures.3 7 Despite this initial surge of activity, it took the EPA a dec-
ade to release its first draft list of chemicals of concern.3 8 The
methods for screening these chemicals are still under
development. 39
Despite the good intentions in establishing EDSTAC and the
attempt to find a way to screen and test for endocrine-disrupting
effects, researchers and regulators ran into the same set of
problems. First, because the science behind low-dose toxicity was
still developing, there was little agreement on how best to reliably
and efficiently test for endocrine-disrupting effects. 40 While screen-
ing individual chemicals seemed difficult, the real goal has been to
find a way to screen the synergistic effects of chemicals, a more ac-
curate reflection of the way individuals and populations actually ex-
perience the world. 41 However, with recent Center for Disease
Control and Prevention (CDC) data providing evidence of hun-
dreds of synthetic chemicals in each of us, the challenge of screen-
ing and testing has become virtually impossible.
It was within this situation that the Data Quality Act (DQA)
entered the legal record buried deep in the budget bill passed in
December 2000.42 The DQA has a slightly sinister, if not uncom-
36. See United States Environmental Protection Agency, Endocrine Primer,
http://www.epa.gov/endo/pubs/edspoverview/primer.htm (last visited Nov. 1,
2008) (providing overview of program's goals and history).
37. See Food Quality Protection Act of 1996, §§ 408 (p)(1)-(2 ), 21 U.S.C.
§ 346a(p) (1)-(2) (2006) (requiring Administrator to develop screening program
to determine whether certain substances have any hormonal or endocrine effect-
ing within two years, and implement plan within three years).
38. See Endocrine Disruptor Screening Program; Chemical Selection Ap-
proach for Initial Round of Screening, 70 Fed. Reg. 56,449 (Sept. 27, 2005)
(describing approach EPA will use for selecting first round of chemicals to be
screened in Endocrine Disruptor Screening Program).
39. See Environmental Protection Agency, Endocrine Disruptor Screening
Program, http://www.epa.gov/endo/pubs/edspoveriew/primer.htm (last visited
Nov. 1, 2008) (explaining program's current implementation efforts).
40. See McLachlan, supra note 30, at 320 (discussing how interdisciplinary na-
ture and relative youth of endocrine disruption created much debate and contro-
versy in field).
41. See e.g., United States Environmental Protection Agency, Endocrine Dis-
ruptor Screening Program; Proposed Statement of Policy, http://www.epa.gov/
fedrgstr/EPA-TRI/1998/December/Day-28/tri34298.htm (noting true goal).
42. See Data Quality Act, Pub. L. No. 106-554, §551, 114 Stat. 2763 (2000)
(directing Office of Management and Budget to issue guidelines to ensure and
maximize "quality, objectivity, utility, and integrity" of information federal agen-
2009]
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mon, history. The DQA passed through Congress in section 515 of
the 7 12-page appropriations bill in December of 2000. Congress
passed the law without hearings, and thus it lacks an official legisla-
tive history. It was inserted by Rep. Jo Ann Emerson at the prompt-
ing of Jim Tozzi, a former Office of Management and Budget
(OMB) official who was then running the Center for Regulatory
Effectiveness. 43
The language in the bill requires the OMB to service com-
plaints made by any organization that feels it is being unfairly regu-
lated due to faulty science. 4 4 The DQA is only one piece of what is
perceived as a "war on science." 45 It certainly fits well within the
larger language game of "sound science" and 'junk science" rheto-
ric that has characterized much of the politics-science nexus for the
past decade or so. 4 6 Whatever the specific politics of the DQA, it
plays two important roles in framing this discussion. First, it has
played a direct role in the regulatory debates that might have let
endocrine-disruptor and low-dose science into the EPA's fold.47
Second, it operates off of the very tension that has perpetuated
these issues more broadly; namely, that science can be certain and
easily translated into the supposedly concrete world of law and
regulation.
With this background in mind, I will now provide a closer look
at the challenges posed to us by Cranor and Fischer by way of the
topics of low-dose toxicity and nanomaterials.
III. EMERGING CHALLENGES: Low DOSE ToxiciTY
AND NANOMATERIALS
Cranor's article provides a creative and provocative approach
to thinking about the challenges posed by emerging sciences and
the ways in which these challenges might be incorporated into a
new, or significantly overhauled, regulatory system. 48 He is con-
cies disseminate). See also Susan M. Bisong, Federal Agencies Subject to Data Quality
Act (Jan. 14, 2003), http://Iibrary.findlaw.com/2003/Jan/14/132464.html; Rick
Weiss, "Data Quality" Law is Nemesis of Regulation, WASH. POST, Aug. 16, 2004, at AOI
(reiterating importance and purpose of Data Quality Act).
43. See DAVID MICHAELS, DOUBT Is THEIR PRODUCT: How INDUSTRY'S ASSAULT
ON SCIENCE THREATENS YOUR HEALTH 178-79 (2008) (discussing legislation).
44. See id. (explaining legislative language).
45. See generally, CHRIS MOONEY, THE REPUBLICAN WAR ON SCIENCE (2005)
(demonstrating example of war on science).
46. See Michaels, supra note 43, at 178-79 (providing author's opinion).
47. See Weiss, supra note 42, at A01 (noting effect on debate).
48. See Cranor, supra note 11, at 251-53 (observing challenges of method of
thinking).
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cerned with how new science can be accommodated within existing
science-based regulatory structures. 49 Drawing on the work of
Thomas Kuhn, Cranor points out that paradigm shifts in science do
not affect science alone;50 rather, shifts in science require concomi-
tant shifts in society.51 Cranor argues that the emerging science
behind low dose toxicity, disease endpoints and human bi-
omonitoring studies have created just such a moment.52 Finding a
place for these new facts, however, has been difficult within the cur-
rent system.
Despite years of an evolving regulatory infrastructure, Cranor
convincingly argues that our current system fails to provide the ba-
sic protections that it is designed, or at least presumed, to offer U.S.
citizens. 53 For Cranor, the evidence clearly establishes that while
specialty synthetic chemicals have continued to be found in human
samples, and studies have shown that timing of exposure, more so
than dose, can be a better predictor for serious outcomes that put
fetuses and young children at greatest risk,54 the U.S. regulatory
system continues to rely upon a fundamentally flawed harm-based
system. 55 This is primarily because current harm-based regulations
rely heavily, if not exclusively, on three approaches: (1) pre-market
screening; (2) pre-market testing; and (3) post-market actions.56
Pre-market screening, as Cranor correctly points out, is incon-
sistent at best, and non-existent at worst.57 Current laws also cover
only a small fraction of the chemicals actually produced for market
use. 58 Producers are required to submit information outlining pos-
sible toxicological effects to the government before these chemicals
reach the market.59 Yet, because there is no legal limit to the
amount of information that must be produced and turned over to
the regulatory agency, most chemicals lack data of any signifi-
cance. 60 Further complicating the matter, is the fact that the vast
49. See id. at 252 (stating concerns of balancing competing scientific
methods).
50. See id. at 251 (commenting on finding of Kuhn's work).
51. See id. (explaining emerging science).
52. See id. at 276 (commenting on impact of emerging science).
53. See Cranor, supra note 11, at 252 (noting failures in current legal system).
54. See id. at 269 (discussing Cranor's belief that timing is more important
than dosage).
55. See id. at 276-88 (explaining flaws in legal system).
56. See id. at 277-84 (providing three possible legislative approaches).
57. See id. at 277-78 (stating worst of three possible approaches).
58. See Cranor supra note 11, at 276-88 (providing commentary on current
state of law).
59. See id. at 252 (noting requirements for producers).
60. See id. at 286-90 (noting insufficient data on chemicals).
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majority of these chemicals were grandfathered into the U.S. regu-
latory system, which yields virtually no health data now or in the
future.
The second approach, pre-market testing, is also woefully out
of date.6' Testing priorities were set years, if not decades, ago,
when current knowledge linking low-level exposures to develop-
mental abnormalities was still an emerging research area. 62 Screen-
ing and testing efforts, therefore, emphasized only priority issues,
such as lethality, and in some cases carcinogenicity. 63
The final approach, post-market laws, represents the retrospec-
tive possibilities for dealing with problems that arise once a chemi-
cal has cleared the pre-market hurdles, but has nonetheless
demonstrated "harm" of one kind or another.64 The approach also
aids in overcoming the problem of chemicals that were
grandfathered in under current regulatory policies. Recourse for
those "injured" in these instances falls under the auspices of tort
law. Here, the burden is on the injured person or persons to
demonstrate the direct link between exposure and injury.
The problem with this entire system, Cranor argues, is that the
emphasis is always on proof of harm, which has been scientifically
validated and vetted. 65 Nevertheless, Cranor rightly asks, why do we
allow harm to happen at all? That is, why is our system designed to
address problems only post hoc, rather than devoting its attention to
preventing harm in the first place? As a basis for this critique, Cra-
nor offers two thoughts based on the flaws of this system and recent
scientific advances. First, the logic of pre- and post-market testing
in the U.S. system is backwards, and greater emphasis on the for-
mer will obviate the need for the latter. It also makes the system
more timely, since building a tort case can take years; years in which
the substance in question continues to be on the market and to
work its way through the ecosystem, carrying it to new bodies
through new exposure routes. Second, according to Cranor, the
presence of a compound (as validated by biomonitoring studies)
already represents a harm. Thus, waiting for the health effect to
manifest is unnecessary since the mere presence of a molecular in-
vader is evidence of a violation.
61. See id. at 277-78 (stating inadequacy of second approach).
62. See id. (providing historical timeline of testing priorities).
63. See Cranor, supra note 11, at 277-78 (explaining shortcomings of pre-mar-
ket testing approach).
64. See id. at 278-80 (discussing framework of post-market regulation).
65. See id. at 279-81 (highlighting difficulties in establishing proof of harm
under current post-market model).
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To overcome the inherent weaknesses of current U.S. regula-
tory approaches, Cranor puts forth two alternative models. They
are dealt with here in reverse order from the way Cranor addresses
them because the permission model, based on the EU REACH
model, is perhaps more familiar and certainly less provocative than
his trespass model; though the REACH model is not without its de-
tractors and skeptics.
The EU REACH program stands as a mirror image to the U.S.
TSCA program for controlling the production and distribution of
potential hazardous chemicals. Attempting to overcome decades of
evaluative neglect, REACH applies retroactively to all chemicals be-
ing produced in the EU or for use and sale in the EU. It attempts
to overcome the limitations of problems faced by TSCA in recent
decades and to accommodate more recent scientific developments
by implementing a three tiered system. First, all chemicals must be
registered with the EU. From there, chemicals (based on known
hazards and quantities to be produced) enter into a system where
they are subjected to increasingly rigorous standards for testing.
Most notable is the use of new developmental data related to toxi-
cology and the emphasis placed on a chemical's potential effects on
those most vulnerable. Authorization by the EU is the final step.
The important difference between the REACH program and
the U.S. system is the REACH program's precautionary approach to
authorization. If a chemical might be a problem, it is not authorized
until data exists which can exonerate it. If, in fact, further research
does provide this counter-evidence, it is released into commerce.
The EU does not wait for a future harm to be proven; future harm
is avoided whenever possible. While critics in the U.S. argue that
the use of a precautionary approach proves illogical, since one can
never prove that a substance will not be harmful in all future in-
stances, this logic is supplemented with a desire to protect the pub-
lic health, even if it means restricting the use of a chemical that is
perhaps "safe" for use.66
A permission-based, pre-market regulatory system, akin to the
REACH program in the EU, has two important effects. First, it
shifts the burden of proof from the plaintiff, arguing that there is a
harm in the post-market environment, and instead requires the
demonstration of safety, within the bounds of current scientific un-
66. For more on REACH specifically and generally, see European Commis-
sion, REACH, http://ec.europa.eu/environment/chemicals/reach/reach-intro.
htm (last visited Nov. 2, 2008) (providing general information about REACH regu-
lation and compliance).
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derstandings, of the chemicals being produced. Second, it poses a
direct challenge to the assumed right to produce chemicals; a right
that, Cranor argues, has proven more salient in recent years than
rights individuals and communities have for protecting themselves.
Indeed, though Cranor does not take his argument this far, there
seems to be a natural connection between the development of
these new sciences and the information they are producing, and
the U.S.-based Right to Know Act. The question is: what do citi-
zens, communities and the public have a right to know? Under the
current administration of this law, we have the right to know very
little. If we judge recent efforts by states to extend the scope of this
doctrine to include, for example, chemicals known to have carcino-
genic, mutagenic, or developmental effects, then perhaps the ex-
tension of this right will prove increasingly difficult. We might,
however, be able to glean the information produced, procured, and
made available from our European counterparts. 67
The permission model, while contentious in its own right, is
not nearly as radical as Cranor's suggestion for the use of a trespass
model as a means of achieving chemical regulation. 68 Cranor care-
fully lays the groundwork in detail in the context of his article. The
basic tenants, and how those might translate into a framework for
regulating chemicals, deserve attention.
Cranor's argument, as I understand it, is based on three points:
(1) the unwanted violation of a person's body by unwanted sub-
stances is a personal wrong, like trespass; (2) trespass does not have
to cause damage to be a wrong; and (3) because we know for sure
that we do have chemicals within us (as exemplified in CDC data)
that entered without our permission, we have been wronged; we
have been trespassed upon or violated. 69 In this case, as indicated
by Cranor, mere presence is already a wrong: a moral wrong.70 Beyond
the philosophical argument that Cranor lays out in support of this
position, he notes that in many contexts, this approach is already
the norm.7' In cases of medical testing where seemingly harmless
acts take place, the law protects the violated patient.72
67. See SCHAPIRO, supra note 5, at 1-19 (advocating adoption of EU methods).
68. See Cranor, supra note 11, at 298-307 (describing trespass model).
69. See id. (detailing theory behind trespass model).
70. See id. at 255 (explaining that in trespass model, presence of chemicals in
body is wrong).
71. See id. at 298-302 (analogizing invasion of chemicals in body with trespass
in other contexts).
72. See id. at 294 (explaining multiple causes of action for patient).
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Cranor offers a compelling argument. The most potent fea-
ture, however, is not the logic of insufficiency that characterizes our
current modes of safeguarding health, but the introduction of a
moral basis for regulation. As it stands, regulation and violation of
those safeguards exemplified by the perpetration of a harm, are
based solely in terms of a strict cause-effect mechanism that links
specific exposure with a specific, quantifiable health outcome. Nev-
ertheless, as Cranor argues, this approach ignores several other im-
portant features of our lives that are incorporated into the law in
other areas.
In his moral argument, Cranor argues that the autonomy of
the individual, within whom we can now undoubtedly locate the
presence of synthetic chemicals, must be respected. 73 Drawing on
examples from private property and trespass cases, as well as the
rights of an individual in medical situations, Cranor attempts to
build a bridge between these areas of the law and current tort law;
the place where individuals currently must plead their cases.7 4
Extending the private property-trespass model becomes diffi-
cult, however, when we consider two basic, but only recently devel-
oped, facts: the inevitability of what Cranor terms "chemical
invasion," and the technologies required for mediating and moni-
toring that invasion. Whereas a typical trespass case has some ele-
ment of control or involves some decision-making process that may
result in trespass, our intimate chemical interaction with the world
virtually guarantees that we will all have some molecular trace of a
chemical that is mass produced at some point. Although this step
may be inevitable, we face the additional challenge posed by the
technoscientific infrastructure necessary to make this violation visi-
ble. Needless to say, access to these resources is not readily availa-
ble to the vast majority.
Cranor's suggestions go a long way in shaping alternative legal
and regulatory frameworks for handling the emerging sciences re-
lated to low-dose toxicity. These suggestions also highlight at least
two places where the intersection between science, law and regula-
tion continue to cause friction. First, the implementation of either
of Cranor's suggested frameworks assumes we know more than we
currently do about the possible harm that exposure to these chemi-
cals may cause. This is not to suggest that there is no evidence that
low-dose chemical exposures do indeed cause harm because the
73. See Cranor, supra note 11, at 302-06 (discussing policy proposals).
74. See id. at 298-302 (comparing invasion of chemicals in body to invasion of
person on another's personal property).
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literature is impossible to ignore in that respect.75 Rather, Cranor's
assertion that pre-market tests must be conducted assumes that
such pre-market tests exist.76 As the EDSTAC program of the EPA
demonstrates, however, developing these tests proves a Herculean
task, one that stretches the very limits of our current scientific
knowledge. The challenge, then, is how to act on the partial infor-
mation that we already have while working to develop a clearer un-
derstanding of the possible harms these chemicals pose.
Second, we must ask, what are the consequences of viewing
bodies, our bodies, as personal property? Cranor makes a strong
argument based on the literature extending out of personal prop-
erty law and medical rights law. 77 This argument, however, might
leave us wondering what this says about the definitional problems
related to bodies and property. Perhaps, more importantly, we
might wonder what this focus on the body does to community-
based contexts upon which so much of current environmental jus-
tice is based. Would a focus on the individual body expand or im-
pede our progress in addressing chemical contamination as an
environmental justice issue?
While Cranor is concerned with the big picture - the failures
of current U.S. regulatory frameworks to accommodate new scien-
tific knowledge - Fischer focuses on one particularly prescient pre-
dicament: the potential toxicological effects of increased
nanotechnology development. 78 His concern, shared with others
working and worrying in this field, is this: how do we reap potential
benefits while, to the extent possible, minimizing the risk?79
Fischer's article focuses on three key elements crucial to the further
development of nanotechnologies: (1) exposure concerns, (2) reg-
ulatory frameworks; and (3) filling in the current knowledge gaps
related to novel technologies.80
When we speak of exposures to nanomaterials, we can think
about three different cases. The first, is exposure in the workplace;
i.e., exposure during the manufacturing process. The second, is
exposure during use of the product. The third, is exposure
75. See e.g., Story, supra note 5, at Cl; Lipton, supra note 5, at C1 (referencing
literature acknowledging effect of low-dose toxicity).
76. See Cranor, supra note 11, at 277-78 (explaining pre-market laws).
77. See id. at 298-302 (discussing trespass model in relation to historical back-
ground of tort law).
78. See Fischer, supra note 11, at 317 (mentioning properties of nanomaterials
that may be hazardous to humans).
79. See id. (summarizing focus of Article).
80. See id. at 315-18 (identifying elements crucial to development of
nanotechnologies).
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through the release of the material into the environment. The
route of exposure is important to understand because in each case
we have the potential involvement of different regulatory bodies.
Additionally, there are different control measures and approaches
in each instance. Finally, as we saw with Cranor's concerns above,
there is the potential for exposures to different segments of the
population.
The latter concerns, those of incidental exposures, have al-
ready caused much trepidation along the lines that this Article has
outlined. The EPA, and to a lesser extent the FDA, have already
laid out what it believes its role is or ought to be.8 ' Data is still
coming in, and much of it is of great concern. Some toxicologists
have attempted to sketch out what a general approach to nano-
materials in the environment might look like, but serious and con-
certed efforts only just now seem to be gaining traction. 2
The more obvious and yet invisible concern of nanomaterials
in a manufacturing facility seems to have far less appeal at the mo-
ment. Nevertheless, in the wake of recent studies that have at-
tempted to liken nanomaterials to asbestos as a possible exposure
model, concerns are growing. 3 Invoking asbestos is a strategic
move for those who want to raise concerns about the unknown po-
tentials behind mass-produced nanomaterials. In both the public
and the workforce, asbestos recalls memories of massive exposure
problems that continue to linger. From a corporate and legal per-
spective, asbestos screams liability and the potential for litigation.
Perhaps more importantly, however, from a technical standpoint,
invoking asbestos attempts to relate what we know about one thing
to something we still do not quite understand. This argument by
analogy is potentially dangerous, yet is important in trying to gain
an understanding of this new area.
In any exposure case, the bigger point is the inevitability of
human and broader ecosystem exposure. We will find nanomateri-
81. See NANOTECHNOLOGY WORK GROUP, ENVTL. PROT. AGENCY, NA-
NOTECHNOLOGY WHITE PAPER 18-21 (2007) (noting what EPA is doing with respect
to nanotechnology); see also NANOTECHNOLOGY TASK FORCE, FOOD & DRUG ADMIN.,
NANOTECHNOLOGY A REPORT OF THE U.S. FOOD AND DRUG ADMINISTRATION NA-
NOTECHNOLOGY TASK FORCE 5 (2007) (explaining task force's mission).
82. See e.g., Gunter Oberd6rster et al., Nanotoxicology: An Emerging Discipline
Evolving from Studies of Ultrafine Particles, 113 ENVrL. HEALTH PERSP. 823, 823 (2005)
(discussing emerging field of nanotoxicology).
83. See generally Craig A. Poland et al., Carbon Nanotubes Introduced into the Ab-
dominal Cavity of Mice Show Asbestos-like Patholgenicity in a Pilot Study, 3 NATURE NA-
NOTECHNOLOGY 423 (discussing study involving nanotechnology which likens
effects to that of asbestos).
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als in human samples in the years to come. The question, then, is
how best to protect the population and the environments within
which we live?
IV. OLD REGULATIONS REBORN OR REGULATION BORN ANEW?
How BEST TO ACCOMMODATE EMERGING SCIENCE?
In light of the challenges that emerging technosciences pose in
the form of new understandings of old materials (e.g., plastics) and
new ones like nanomaterials, we face the question of how best to
protect ourselves and our ecosystems.
Cranor and Fischer, in their own ways, offer some ideas about
the directions that we might take. Fischer, in highlighting the pos-
sible problems presented by a specific class of emerging technolo-
gies, demonstrates both the inadequacies of current regulatory
frameworks, but also a way to make them work in the present and
future without much restructuring.84 By addressing definitional,
classificatory and knowledge gaps that nanomaterials present, he
hopes to fit these technologies into current systems, however bro-
ken they may be. His attempts to do so are not new; indeed, some
of the earliest legal wrangling and head scratching over the possible
problems associated with nanomaterials were exactly along these
lines.85
Yet, this may not be a good sign. In the decade since those
earlier musings, how far have we come? Why are we still struggling
with these same sets of questions? To be sure, Fischer is not alone
in arguing that the best way forward is through a modification of
existing frameworks, if only to provide consistency and to protect us
more immediately while the specifics are negotiated.8 6 Nonethe-
less, this reasoning seems to be resting on the logic of the treadmill:
research in these areas is already taking place; such research will
not stop, and, therefore, we must use whatever protections are avail-
able while we still can. While this may be the simplest and most
immediately plausible way of framing protections from emerging
nanomaterials, the potentially flawed logic is left squarely in place.
84. See Fischer, supra note 11, at 325-30 (explaining how regulatory challenges
can be met).
85. See Frederick A. Fiedler & Glenn H. Reynolds, Legal Problems of Na-
notechnology, 3 S. CAL. INTEROisc. L.J. 593, 594-95 (1994) (discussing legal issues
associated with nanotechnology).
86. See generallyJ. CLARENCE DAVIES, WOODROW WILSON INT'L CTR. FOR SCHOL-
ARS, NANOTECHNOLOGY OVERSIGHT: AN AGENDA FOR THE NEW ADMINISTRATION
(2008), available at http://207.58.186.238/process/assets/files/6709/pen13.pdf
(providing plan regarding nanotechnology for beginning months of new
administration).
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Cranor's work questions precisely this logic. Why are we on a
treadmill at all? Why can we not get off, or at least slow it down
until we can figure out the proper safeguards? Indeed, if we use the
recent examples of BPA and phthalates as any kind of guide, then
we might want to proceed into the future at a much slower pace.
This is how I interpret Cranor's methods: question the logic of pro-
gress by replacing assumptions. While we assume a right to produce
new goods, maybe we should assume permission to produce new
goods. When we lack data on safety, we assume everything is just
fine or safe until we learn otherwise. Perhaps we should take a
more precautionary stance on behalf of ourselves, our communities
and our ecosystems.
Yet, we should note the politics now embedded in the word
"precaution," and its manifestation in the Precautionary Principle.
The most recent incarnation of the principle emerged from the
Wingspread Conference in Racine, WI in 1998 (which Cranor par-
ticipated in) as a general principle for dealing with emerging sci-
ence related to health and the environment. The principle reads:
"[w]here an activity raises threats of harm to the environment or
human health, precautionary measures should be taken even if
some cause and effect relationships are not fully established scien-
tifically."'87 Cranor, in his paper, argues for ways in which this prin-
ciple can become a reality. It involves taking steps ahead of time
(pre-market testing), and a reliance on what we do know rather
than what we do not. Cranor, echoing advocates of REACH, goes
further in arguing that the responsibility for filling in these gaps
ought to be placed on the producers.
Nevertheless, whether we are talking about new technologies
such as nanomaterials, or simply new information about old materi-
als, as in the case of BPA and phthalates, the challenge is the same:
how do we accommodate emerging knowledge into our regulatory
frameworks? Right now, the system of linkages among science, law
and regulation does not readily allow this to happen. A case can be
made, however, for working within existing structures or rebuilding
them anew as Cranor suggests, and as the EU has recently done by
way of its REACH program.
Working within the current structure provides consistency in
application and an immediate response. This is perhaps one rea-
son why this approach has been advocated by those working in, or
87. See Wingspread Statement on the Precautionary Principle, http://
www.gdrc.org/u-gov/precaution-3.html (last visited Nov. 2, 2008) (advocating pre-
cautionary approach concerning release of toxic substances) (brackets added).
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formerly associated with, regulatory bodies.a8 Yet, there are also
many weaknesses with this approach. The regulatory system has
been slow to react, whether due to the long delays in incorporating
endocrine-disrupting data or failing to articulate a clear stance on
nanomaterials. Perhaps this latter event is one reason why some
groups have taken it upon themselves to create their own quasi-
regulatory research frameworks, which itself is an interesting devel-
opment in the regulatory world.89  Most importantly, working
within the current structures fails to open the debate to important
discussions involving the underlying philosophical assumptions of
regulation. How can we move beyond strict scientific reasoning to
incorporate a more traditional moral aspect to regulation? How do
we balance the rights of the corporation with the rights of the indi-
vidual that will inevitably be subject to the presence of corporate
goods within each of us? How do we balance the right to produce
(if it is indeed a right) with the right to protect oneself or to not
subject oneself to certain molecular exposures? I cannot be sure
that simply tinkering with TSCA, as many are advocating, will allow
for these sorts of questions to be asked, let alone answered.9 0
In the end, what we are looking for is a way to exist in the
world that Ulrich Beck describes as a "risk society."9 1 Within the
world that we currently inhabit, characterized by risk, we can no
longer identify the sources of our risk. Legal and regulatory sys-
tems that attempt to tease out direct connections between polluter,
emissions, exposure and health consequences, are operating in a
world that no longer exists. Each day all of us are bombarded with
the effluence of our affluence. Our chemical bodies mix and min-
gle with the molecules of the world, now including scores of
thousands that did not previously exist just a few years or decades
ago. Our bodies are now distinctively chemically different than pre-
World War II generations. The result is that our sciences, which
gave birth to these many miraculous molecules, can no longer keep
88. See SAMUEL N. LOUMA, WOODROW WILSON INT'L CTR. FOR SCHOLARS, SIL-
VER NANOTECHNOLOGIES AND THE ENVIRONMENT: OLD PROBLEMS OR NEW CHAL-
LENGES (2008), http://www.nanotechproject.org/process/assets/files/7036/
nano-pen-15-final.pdf (observing possible reason for advocating working within
current structure).
89. See EN% TL. DEF. - DUPONT NANO P'SHIP, NANO RISK FRAMEWORK, (2007),
http://www.edf.org/documents/6496 Nano%20Risk%2OFramework.pdf (setting
forth nano risk framework guidelines).
90. See LUOMA, supra note 89 (arguing that TSCA should be made to accom-
modate emerging technologies such as nanomaterials).
91. See ULRICH BECK, RISK SOCIETY: TOWARDS A NEW MODERNITY, 19-50 (Mark
Ritter trans., Sage 1992) (1986) (describing conflicts that arise in highly technolog-
ical society).
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pace with understanding the world that they have created. Con-
comitantly, neither can legal nor regulatory frameworks that seek to
apply this old logic to our new circumstances. What is needed is a
framework that understands that the environment is now different
and our bodies are now different, and that as a consequence, we do
not yet fully understand what these bodies in these environments
are becoming. We need a framework that will accommodate new
knowledge as it emerges out of new sciences, such as genetic toxi-
cology, endocrine-disrupter science, bioinformatics and, perhaps
broadly, sustainability science. In this world, knowledge is contin-
gent and still evolving, yet this should not prevent us from taking
action through our democratic tools of law and regulation. Indeed,
we must make these institutions as flexible as the current science.
We need a space where science, law and regulation can work to-
gether, without colliding.
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